Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Clinical trial NCT06229340 · RECRUITING

Trial details

NCT number: NCT06229340
Sponsor: N.N. Petrov National Medical Research Center of Oncology
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

RAS Mutation Ras (Kras or Nras) Gene Mutation Colorectal Cancer Recurrent Pancreas Cancer Lung Cancer Melanoma Refractory Cancer

Start date: 2023-10-03
Primary completion: 2026-10-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.